IN THE SPOTLIGHT

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC | ...

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC | ...

Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced ALK-Rearranged NSCLC

Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced ALK-Rearranged NSCLC

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

迈向精准时代:EGFR突变可切除NSCLC的围术期全程管理策略_腾讯新闻

迈向精准时代:EGFR突变可切除NSCLC的围术期全程管理策略_腾讯新闻

Enrolment concludes in Phase III trial of Dizal’s sunvozertinib for NSCLC

Enrolment concludes in Phase III trial of Dizal’s sunvozertinib for NSCLC

Key Abstracts in Early-Stage NSCLC From ASCO 2025

Key Abstracts in Early-Stage NSCLC From ASCO 2025

EGFR+ NSCLC: Experts Weigh Risk vs Reward at ASCO 2025

EGFR+ NSCLC: Experts Weigh Risk vs Reward at ASCO 2025

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights